Lutathera® (lutetium Lu-177 dotatate) is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) to deliver targeted radiation to somatostatin-receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Lutathera market refers to global adoption, sales, production and clinical use of this specific drug product and the broader demand f... https://www.metatechinsights.com/industry-insights/lutathera-drug-market-2402